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CAPABILITIES OF MIR-24 IN EXOSOMES IN BREAST CANCER CELLS 
CAITLYN KUSNIERCZYK 
ABSTRACT 
 Circulating tumor cells are cells that break away from a primary malignant site 
and circulate in the blood stream. From there, they can relocate to another part of the 
body, and cause metastasis. They can be used as biomarkers for cancer prognosis, and 
may also be used for cancer diagnosis in the presence of comorbid conditions. Micro 
RNAs (miRNA) are non-coding small RNAs found in humans that can degrade or 
upregulate protein transcription. miRNA is dependent on the Argonaute2 protein for 
incorporation into an RNA-induced silencing complex. miRNA utilizes exosomes to 
move outside the cytosol while being protected from extracellular enzymes such as 
RNases. miR-24 is implicated in many cancers, including breast cancer, and has the 
ability to upregulate the expression of its neighboring genes. As it has been shown that it 
can use the 3’untranslated regions on mRNA to influence expression of nearby targets, it 
also may influence its own transcription. The aim of this study was to evaluate the 
capability of transfected miR-24 to translocate into the nucleus of MCF-7 cells. It also 
evaluated the ability of transfected mirR-24 to integrate into exosomes, and whether this 
exosomal miRNA could similarly integrate into the nucleus in newly cultured cells. 
Results showed that transfected miR-24 does translocate into the nucleus of MCF-7 cells. 
It also showed that transfected miR-24 readily incorporates into exosomes. Because of 
procedural difficulties and time constraints, transfections with exosomal miR-24 have not 
yet been completed, but are a key next step in illustrating the ability of miR-24 to 
	
	 vi 
influence genetic expression on a broad spectrum. As miR-24 is upregulated in many 
disease states, including in many forms of breast cancer, the use of exosomes may outline 
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Cancer is the cause of millions of deaths worldwide. Its variation in cause, 
mechanism of action, risk factors, primary site, symptoms, high-risk populations, and 
effective treatments make it an incredibly difficult disease both to diagnose and treat. 
Incidence of cancer diagnoses increases as rapidly as cancer research develops, meaning 
the need for more in-depth understanding of cancer mechanisms and new novel therapies 
is as important as ever. Breast cancer is one of the most fatal subtypes of the disease, and 
is equally as diverse in its forms. Breast cancer has many associated genetic mutations, 
including the BRCA gene, and hormonal risk factors like the HER2 receptor. Early 
diagnosis is critical to long-term survival. Research has shown that circulating tumor 
cells (CTCs) are a potential diagnostic and prognostic tool for all cancers. CTCs are 
cancerous cells that escape from the primary tumor site and flow through the 
bloodstream. They are capable of creating distant metastases as well as causing relapse 
following successful cancer treatment. While many studies and clinical trials have 
explored the use of CTCs, there has yet to be a standard for their routine use in cancer 
diagnosis and treatment.  
Currently, the CellSearch system is the only FDA-approved CTC detection tool, 
and is the gold-standard for clinical usage. In the CellSearch system, a blood sample is 
centrifuged to separate plasma from solid components, and CTCs are magnetically 
separated from other cells through the addition of ferrofluid nanoparticles with antibodies 
that bind epithelial cell adhesion molecules (EpCAMs) on the CTC surface. The 
separated CTCs are then fixed and stained with epithelial cell-specific cytokeratin 
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antibodies. Any contaminating leukocytes are identified by the addition of a monoclonal 
antibody specific to leukocyte-marker CD45. A DNA-stain, DAPI, is added to the cell 
sample, and cells are loaded onto a magnetic cartridge that aligns all cells into a single 
focal depth for analysis. The system then identifies CTCs, which are presented to the 
operator for confirmation and analysis.  
A limitation of the CellSearch system is that it relies on EpCAMs to identify 
CTCs. CTCs may undergo epithelial-to-mesenchymal transition, which will allow them 
to go undetected in the CellSearch system (Austin et al., 2018). Additionally, this 
technology is inapplicable for mesenchymal malignancies such as sarcomas (Austin et 
al., 2018). Other, non-EpCAM-based technologies have been proposed, but are not yet 
used in clinical settings. These technologies include the use of dendrimers as well as 
magnetic, gold, or silver nanoparticles (Austin et al., 2018). While these assays are 
promising prospects for addressing gaps in the isolation of CTCs, they have not yet been 
tested against CellSearch technology in clinical practice (Austin et al., 2018).  
Because the CellSearch method requires cell fixation, this system cannot 
concretely determine the function of CTCs (Coumans & Terstappen, 2015). Therefore, it 
cannot characterize a special subtype of metastasis-initiating cells (MICs), cells found 
within a  CTC population (Baccelli et al., 2013). An in vivo assay was designed for 
screening metastatic breast cancer patients with CTCs for MICs, with the hope of 
characterizing the specific CTCs that lead to metastasis (Baccelli et al., 2013). After 
injecting these CTCs into a xenograft, the cell populations where metastases developed 
were analyzed. This provided a profile of MICs, which were CD44+, CD47+, and MET+, 
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in addition to EPCAM+, the characteristic that allowed for their initial isolation with 
CellSearch (Baccelli et al., 2013). These experiments illustrated that while CellSearch 
technology still functions as an initial identification method for CTCs, it can benefit from 
novel qualitative methods for CTCs to provide a better profile of the specific cells 
responsible for cancer metastasis. Because this characterization is still CellSearch-
dependent, further technological advances are needed so that cancers hallmarked by an 
epithelial-to-mesenchymal transition may have CTC profiles as well.  
Folate receptor a (FRa) is highly expressed in many cancers, and its detection via 
ligand-targeted PCR is a way to quantify CTCs using already-established technology (L. 
Chen et al., 2018). Utilization of FRa as a CTC marker has been primarily tested in non-
small cell lung cancer cell lines, but as this receptor is also expressed in breast cancer, 
future research may reveal that this is another way to characterize CTCs for other cancer 
types as well.  
Despite gaps in identification technologies, many studies have already 
demonstrated the numerous clinical applications of CTCs. High levels of CTCs are 
associated with a poorer disease prognosis. They are also associated with cancer 
recurrence even after successful treatment, and can predict metastasis before they are 
apparent through clinical symptoms or radiology (Huang et al., 2015). In breast cancer 
specifically, CTCs have shown to be a stable prognostic marker for both early-stage and 
metastatic cases (Zhang et al., 2012). Another potential use of CTC detection is as a 
diagnostic marker for patients with comorbid conditions that leave them at a higher risk 
for developing cancer (Ilie et al., 2014). This was explored in patients with chronic 
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obstructive pulmonary disease (COPD), as this population has an increased risk for lung 
cancer (Ilie et al., 2014). A group of COPD patients with high CTC counts was identified, 
and patients received increased screening for the development of lung cancer (Ilie et al., 
2014). Each patient included in the study developed lung cancer, but because of the 
increased screening, the cancer was detected early (stage IA in each patient) and eligible 
for surgical resection (Ilie et al., 2014). Without this increased screening because of the 
high CTC count, the prognosis for each patient may have been drastically different. This 
clinical application of CTC detection may be applied to other comorbid conditions. 
Recently, research has demonstrated the epigenetic applications of CTCs in breast cancer. 
Hypomethylation of CTC clusters is associated with poor prognosis in breast cancer, and 
using Na+/K+-ATPase inhibitors can break up CTC clusters to remodel DNA methylation 
with the goal of suppressing metastasis (Gkountela et al., 2019).  
 Overall, as studies have shown the enormous landscape of therapeutic potential, 
there is a great need for more research into these cells. From acting as a diagnostic 
marker to foreshadowing the efficacy of adjuvant therapy to predicting prognosis, CTCs 
are relevant in every area of clinical practice. 
Micro ribonucleic acids, known as miRNAs, are a subclass of RNAs found 
endogenously in humans (Cai et al., 2009). They are characterized by their small size, as 
their length typically ranges from 18-22 nucleotides, and that they are non-coding RNAs. 
Because of limitations in research methods, the importance of miRNA function went 
unnoticed for many years, until two discoveries were made of miRNA-mediated gene 
regulation (Cai et al., 2009). In 1993, research identified that miRNA lin-4 downregulates 
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LIN-14 in C. elegans, a protein critical to early development, by blocking its translation 
via antisense interactions (Lee et al., 1993). Subsequent research showed that let-7 
miRNA regulates gene expression for lin-4 (Reinhart et al., 2000). Together, these studies 
illustrated that a series of miRNA-controlled regulatory events were responsible for 
dictating development in C. elegans (Reinhart et al., 2000).  
 The best established model of miRNA biosynthesis is referred to as the canonical 
pathway, which is thought to be conserved amongst vertebrates and invertebrates (Yang 
& Lai, 2010). In this model, primary miRNAs containing “hairpin” structures are 
identified. An RNase III enzyme, Drosha, and double-stranded RNA binding protein 
DGCR8 form a nuclear microprocesser complex, which cleaves the hairpin structures so 
they may be transported to the cytoplasm (Yang & Lai, 2010). Once in the cytoplasm, 
another RNase III enzyme, Dicer, cleaves the hairpins at their terminal loop, producing 
miRNA-miRNA pairs (Yang & Lai, 2010). One miRNA strand can then be loaded into 
an Argonaute protein-based complex to form an RNA-induced silencing complex (RISC) 
(Yang & Lai, 2010). Incorporation into a RISC is the primary mechanism by which 
miRNAs modulate gene activation and repression (Yang & Lai, 2010). The RISC binds 
target mRNA sequences based on the sequence of the incorporated miRNA strand (Yang 
& Lai, 2010). The canonical pathway is illustrated in Figure 1A.  
 Certain miRNAs deviate from the canonical model and utilize alternative 
pathways. One example of this is miRNA-451. It is proposed that after cleavage by the 
Drosha-DGCR8 complex, pre-miRNA-451 is 42 nucleotides in length (approximately 
double the length of a normal miRNA) and must undergo additional processing before it 
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can be integrated into a RISC (Yang & Lai, 2010). miRNA-451 is dependent on AGO2 
for its RISC formation. The miRNA-451 pathway is shown in Figure 1B.  
 
 
Figure 1: Models of miRNA Biogenesis. Schematics of the canonical pathway (A) and 
the miR-451 pathway (B) for miRNA biogenesis. (Yang & Lai, 2010) 
 
Once synthesized, miRNAs regulate gene expression by binding complementary 
sequences in mRNA (Yang & Lai, 2010). Typically, miRNA binds target sequences 
found in the 3’ untranslated regions (3’UTR) with the purpose of translational silencing 
or degradation (Yang & Lai, 2010). miRNA also are capable of enhancing transcription 
of neighboring genes (Xiao et al., 2017).   
Argonaute proteins are a fundamental component of the RISC, and are known for 
their key role in post-translational gene silencing. AGO2, in particular, is responsible for 
the “slicer” activity that is responsible for producing mature miRNA and mRNA 
degradation. One study demonstrated the importance of AGO2 by engineering a mutant 
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mouse model with a silenced AGO2 gene (Cheloufi et al., 2010). AGO2-/- mice were 
anemic and did not survive (Cheloufi et al., 2010). Analysis revealed that the loss of 
miRNA-451 inhibited normal erythropoiesis resulting in anemia (Cheloufi et al., 2010). 
Because miRNA-451 relies on AGO2 to form its RISC, AGO2 is a critical protein for 
vertebrate development (Cheloufi et al., 2010).  
It is well-established that blood plasma contains extracellular nucleic acids in both 
the healthy population and in people with illness (Fleischhacker & Schmidt, 2007). In 
cancer patients, characterizing the circulating nucleic acids found in the plasma often 
reveals DNA mutations or overexpression of RNA that upregulates tumor-related genes 
(Fleischhacker & Schmidt, 2007). The existence of circulating nucleic acids raised the 
question of whether or not circulating miRNA is part of the profile of extracellular 
nucleic acids found in the plasma (Mitchell et al., 2008). Size characterization of the 
RNA profile isolated from blood plasma showed that miRNA was in fact found in 
circulation in healthy human populations (Mitchell et al., 2008). Because RNase activity 
is high in plasma, the stability of miRNA is critical for its use as a biomarker for disease 
(Mitchell et al., 2008). Despite the susceptibility of naked miRNA to RNase activity, 
endogenous miRNAs showed resistance to degradation, demonstrating their stability in 
plasma (Mitchell et al., 2008). To demonstrate the ability to detect tumor-specific 
miRNAs in plasma, a mouse model was injected with a human prostate cell line, and 
miRNA levels were compared to a control group (Mitchell et al., 2008). Relative 
quantitative levels of miRNA-629 and miRNA-600 were measured because there are no 
known murine homologs for these miRNAs (Mitchell et al., 2008). Measuring levels of 
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these tumor-associated miRNAs distinguished between the control and xenograft groups 
with 100% specificity and selectivity (Mitchell et al., 2008). Plasma analysis showed that 
these miRNAs were primarily found in the plasma, and thus stable in blood (Mitchell et 
al., 2008).   
In order to use miRNAs as a biological marker, it is important to understand the 
mechanism by which they enter the bloodstream, and how they avoid degradation by 
extracellular RNases. It was discovered that upregulation of miRNA in cells leads to 
increased secretion of miRNA in the bloodstream, and that introducing an apoptotic 
agent, such as cisplatin, there is no increase of extracellular miRNA (Kosaka et al., 
2010). This suggests that miRNA is actively secreted from cells, and that secretory 
concentration is dependent on intracellular concentration. It was theorized that miRNA 
fragments were contained in endosomal sorting complexes required for transport 
(ESCERT), and thus protected from enzyme degradation outside the cell. Experimental 
characterization suggested that single-stranded RNA was preferentially released from 
cells, and the secreted RNA was primarily contained in exosomes (Kosaka et al., 2010). 
When exosomes were extracted in RNase-containing media, miRNA remained stable, 
suggesting that the exosomes are what protect the miRNA from degradation (Kosaka et 
al., 2010). Exosomes secretion is controlled by ceramide biosynthesis and neutral 
sphingomyelinase 2 (nSMase2), an enzyme that mediates the ceramide biosynthesis 
pathway (Kosaka et al., 2010). When cells were treated with an nSMase2 inhibitor, 
GW4869, extracellular miRNA expression was reduced correlated to inhibitor dose, 
while levels of intracellular miRNA remained unchanged (Kosaka et al., 2010). 
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Treatment with GW4869 reduced exosome secretion into the media, but the contents of 
the exosome, including the quantity of miRNA, remained unchanged (Kosaka et al., 
2010).  
Exosomes act as protective capsules for miRNA outside the cell. Exosomes are a 
subpopulation of intraluminal vesicles (ILVs). Multivesicular bodies in the cytosol, 
containing small ILVs, fuse with the plasma membrane. ILVs are then released from the 
cell into the extracellular space as exosomes. Exosomes can form from two pathways 
beginning at the endosomal membrane: an ESCERT-dependent pathway and an 
ESCERT-independent pathway (Edgar, 2016). In the ESCERT-dependent pathway, the 
ESCERT machinery processes ubiquitin-tagged endosomes (Edgar, 2016). The ESCRT 
clusters the tagged proteins together, curving the endosomal membrane and producing 
ILVs (Edgar, 2016). The ESCRT-independent pathway is less established, but as ILVs 
still form when ESCRT machinery is not present, an independent pathway must exist 





Figure 2: Overview of Structural Features and Functions of Exosomes. Illustration 
showing structural characteristics and formation of exosomes from intraluminal vesicles 
(Edgar, 2016).  
 
While the most established functions of miRNAs are translational silencing and 
mRNA degradation, miRNAs can also act as transcription enhancers. One study 
investigated the role of miR-24 as an enhancer. As shown in Figure 3, miR-24 acts as an 
enhancer for its neighboring genes, FBP1 and FANCC, increasing their protein levels 
(Xiao et al., 2017). Accordingly, inhibiting miR-24 results in significantly less mRNA for 
these two genes (Xiao et al., 2017). This function is AGO2 dependent, as repeating these 
results with an AGO2 knockout showed significantly less expression of FBP1 and 
FANCC (Xiao et al., 2017). Interestingly, miR-24-1 is able to act as an enhancer of these 
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genes while simultaneously functioning in the canonical miRNA pathway (Xiao et al., 
2017). As AGO2 is a fundamental protein for producing mature miRNA, it is also 
fundamental to the ability of miR-24 to upregulate gene expression.  
 
Figure 3: miR-24-1 Acts as an Enhancer for Neighboring Genes FANCC and FBP1.  
Addition of an miR-24-1 mimic significantly increases expression of both neighboring 
genes (FANCC and FBP1) (A); knockout of miR-24-1 (antagomir) significantly 
decreases their relative expression (B). (Xiao et al., 2017).  
 
  The FANCC gene plays a role in the Fanconi anemia (FA) pathway. This pathway 
is activated by DNA damage, and therefore blocks DNA replication (Deakyne & Mazin, 
2011). The FANCC protein is a core member of a larger protein complex, the FA 
complex, and its gene is one of the most commonly mutated in FA (Deakyne & Mazin, 
2011). Interestingly, proteins in Group III of the FA complex are identical to proteins 
associated with breast cancer (Wang, 2007). Notably, FANCD1 is the same protein as 
BRCA2, and FANCN is the same as BRCA2-partner PALB2 (Wang, 2007). These 
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similarities illustrate the close relationship between the FANCC gene that is upregulated 
by miR-24 and breast cancer.  
Interestingly, miR-24 has been proven to be upregulated in a variety of disease 
states. H2AX is a histone protein that regulates the response to double-stranded DNA 
damage. The 3’UTR of H2AX contains binding sites for miR-24 (Lal et al., 2009). In 
terminally differentiated cells, miR-24 is upregulated, reducing the expression of H2AX 
and resulting in suppressed capacity to repair DNA breaks (Lal et al., 2009).   
miRNAs are known to travel in exosomes. It has even been proposed that the 
delivery of miRNAs can confer resistance to chemotherapies (W. Chen et al., 2014). In 
MCF-7 breast cancer cell lines, miR-141 and miR-34a were associated with docetaxel 
resistance (Kastl et al., 2012). In the cells that exhibited docetaxel resistance, increased 
miR-34a expression resulted in increased expression of BCL-2 and CCND1 (Kastl et al., 
2012). BCL-2 expression is linked to decreased apoptosis, which could be a mechanism 
for docetaxel resistance (Kastl et al., 2012).  
Because of the diversity in miRNAs, the true extent of their capabilities is 
unknown. If miRNAs can both downregulate and enhance transcription of neighboring 
genes, they may be able to affect their own expression. Increased miRNA expression may 
create a positive feedback loop as it continues to upregulate its own expression. These 
effects can be amplified if miRNAs are utilizing exosomes to move from cell to cell, as 
miRNAs may recruit additional cell machinery increase their own transcription.  By 
doing so, they may confer chemotherapy resistance to circulating tumor cells, providing a 
mechanism for treatment-resistant metastasis. With the prospect of exosomal circulation 
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and possible self-regulation, there are many mechanisms by which miRNAs may affect 






The specific aim of this study was to test the hypothesis that mir-24 can move 
between cells via exosomes, and integrate into the nucleus of a new host cell. There were 
three goals to illustrate this hypothesis. First, it aimed to illustrate miR-24 is found in 
exosomes in MCF-7 cells. Second, it sought to prove that if miR-24 was introduced to 
MCF-7 cells via transfection, the miR-24 would translocate to the nucleus of the MCF-7 
cells, illustrated through immunofluorescent staining. Finally, it intended to show that 
fixed MCF-7 cells transfected with exosomes extracted from other MCF-7 cells would 






Immunofluorescence images were generated via NIS Elements Advanced Research 




MCF-7 cells were cultured using DMEM media, prepared with 10% fetal bovine serum 
(FBS), and 1% penicillin and streptomycin. Cells were cultured either in 10cm or 6-well 
plates. Cells were incubated and subcultured on a three-day schedule. The incubator 
temperature was set to 37oC, and the atmosphere consisted of 95% O2 and 5% CO2. FBS 
was obtained from Atlanta Biologics, and DMEM media, streptomycin, and penicillin 
were obtained from Fischer Scientific.  
 
miRNA Transfection 
MCF-7 cells were cultured in DMEM as prepared above. OptiMEM-miRNA mixture 
(Table 1) and OptiMEM-RNAiMAX mixture (Table 2) were prepared. OptiMEM 
Reduced Serum Media and Lipofectamine RNAiMAX Transfection Reagent were 
purchased from ThermoFisher Scientific.  
Table 1: Preparation of OptiMEM-miRNA Mixture for Transfection of MCF-7 
Cells.  
 
Volume Required for 
Individual Well on 6-Well 
Plate (uL) 
Total Volume Required for 
6-Well Plate (uL) 
OptiMEM 125 750 
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miRNA 2.5 15 
 
Table 2: Preparation of OptiMEM-RNAiMAX Mixture for Transfection of MCF-7 
Cells.  
 Volume Required for 
Individual Well on 6-Well 
Plate (uL) 
Total Volume Required for 
6-Well Plate (uL) 
OptiMEM 125 750 
RNAiMAX 7.5 45 
 
Once each mixture was prepared, the miRNA and RNAiMAX mixtures were combined 
at RT for 5 minutes. After 15 minutes, 250uL of was added to each well of a 6-well plate 
containing cultured cells in media, slowly in a circular motion.  
 
RNA Extraction 
Media was removed from MCF-7 cells via aspiration. TRIzol was added directly to the 
cells for lysis (1mL for each well of a 6-well plate, or 2mL for a 10cm plate). Solution 
was pipetted until cells were lysed, and transferred to microcentrifuge tubes, and 
incubated in the TRIzol for 5 minutes at RT. 200uL of chloroform was added for each 
1mL of TRIzol used. Microcentrifuge tubes were vortexed for 15 seconds, and incubated 
in the solution for 3 minutes at RT. Samples were centrifuged for 5 minutes at 12,000 x g 
at 4oC for phase separation. The aqueous phase containing the RNA was transferred to a 
new microcentrifuge tube. A volume of isopropanol equal to the volume of the aqueous 
phase was added to the tube, and incubated at RT for 10 minutes. The tube was then 
centrifuged at 12,000 x g for 10 minutes at 4oC. The supernatant was removed, and the 
RNA pellet was washed with 800uL of RNase-free 70% ethanol. The ethanol was 
completely removed with a pipette, and the RNA pellet was dried for 5 minutes at RT. 
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The RNA pellet was then mixed with 30uL of RNase-free water, and ready for Nanodrop 
quantification of the RNA concentration within the sample.  
 
Exosome Extraction 
Total Exosome Isolation Reagent was purchased from ThermoFisher Scientific. FBS-free 
DMEM media was harvested from transfected MCF-7 cell culture. The cell media was 
centrifuged at 2000 x g for 30 minutes at 4oC, and the supernatant, the cell-free culture 
media, was transferred to a fresh tube without disrupting the cell pellet at the base. 10mL 
of the cell-free culture media was moved to a new tube, and mixed with 5mL of the Total 
Exosome Isolation reagent. The mixture was mixed into a homogenous solution, and 
incubated at 4oC overnight. After incubation, it was centrifuged at 10000 x g for 1 hour at 
4oC. The supernatant was discarded, and the pellet containing exosomes was resuspended 
in 100uL of PBS. Isolated exosomes were stored at -20oC.  
 
Reverse-Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) 
RNA was extracted and quantified using a NanoDrop spectrophotometer from 
ThermoFisher Scientific. Samples were prepared for reverse transcription, as seen in 
Table 3.  
Table 3: Preparation of RNA for Reverse Transcription for RT-qPCR using 
ThermoFisher Scientific TaqMan Reverse Transcription Kit. 
 Volume (uL) 
MCF-7 RNA (1000ng/6uL) 6 
Reverse Transcription Primer Pool 6 
dNTPs with dTTP (100mM) 0.3 
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MultiScribe Reverse Transcriptase (50U/uL) 1 
10X RT Buffer 1.5 




Reverse transcription was run on a Bio-RAD MyCycler Version 1.065 Thermal Cycler 
for 30 minutes at 16oC, 30 minutes at 42oC, 5 minutes at 85oC, and held at 4oC. cDNA 
was then prepared for qPCR with ThermoFisher Scientific Sybr Green Master Mix and 
water, and run using a standard qPCR protocol.  
 
Protein Extraction 
Media was aspirated from MCF-7 cells. Cells were washed with PBS. Then 120uL of 2% 
SDS, which acted as a lysis buffer, was added. Protein was moved to a microcentrifuge 
tube and boiled at 100oC for 20 minutes.   
 
Western Blot 
8% Tris-glycine stacking and loading gels were prepared (ten 1.5 mm wells). Protein 
samples and ThermoFisher Scientific Invitrogen Molecular Weight Standard were loaded 
into prepared gels. Samples were initially run at 80 A for 15 minutes, then at 150 A until 
samples appeared ready for transfer, and then kept at 50 A for a final 20-minute interval. 
Samples were transferred to a nitrocellulose membrane by running a transfer apparatus at 
400 mA for 90 minutes at 4oC. After transfer, the nitrocellulose membrane was blocked 
in a 5% milk in TBS-T solution for 1 hour at RT. The membrane was then incubated in 
primary antibody (Table 4) at 4oC overnight on a shaker. Primary antibody was then 
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removed, and the membrane was washed three times with TBS-T at 5-minute intervals. 
The membrane was then incubated in secondary antibody (Table 4) for 1 hour at RT on a 
shaker, and subsequently washed three times with TBS-T at 5-minute intervals. For 
imaging, the membrane was developed in a dark room using film and Hyglo® Quick 
Spray. 
Table 4: Antibodies Used for Western Blotting.  
Primary Antibody Used Corresponding Secondary Antibody 
AGO2 Monoclonal Antibody (Rabbit) 
(1:1000 Dilution in TBS-T) 
HRP Goat Anti Rabbit Secondary 
Antibody (1:2000 Dilution in TBS-T) 
ACTIN Monoclonal Antibody (Mouse) 
(1:1000 Dilution in TBS-T) 
HRP Goat Anti Mouse Secondary 
Antibody (1:2000 Dilution in TBS-T) 
 
Immunofluorescence Staining  
Cover slips were added to a 6-well plate, and MCF-7 cells were cultured according to the 
procedure above.  Cells were transfected as controls, negative controls (NC), or miR-24 
groups according to transfection procedure (see above). Duration of transfection and time 
period before fixation can be found in Table 4.  
Table 5: Transfection and Incubation Periods for MCF-7 miR-24 Transfections for 
Immunofluorescence Staining. 
Figure(s) Duration of Transfection 
Duration of Incubation 
Between Transfection and 
Fixation 
8-9  8 hours 0 hours 
10-16 24 hours 24 hours 
17 24 6 
18 24 18 




Media was aspirated, and cells were rinsed with 2mL ThermoFisher Scientific pH 7.4 
PBS at room temperature (RT). Cells were fixed with 2mL of freshly made 4% 
paraformaldehyde in PBS for 10 minutes at RT away from light. After fixation, cells 
were rinsed three times with PBS. Cells were permeabilized with 0.5% Triton X-100 in 
PBS-T for 10 minutes away from light, and rinsed three times with PBS. Cells were 
blocked in 3% bovine serum albumin (BSA) in PBS for 10 minutes with the purpose of 
preventing non-specific binding of antibodies. Cover slips were then placed cell-side 
down in 80uL of a 1:1000 dilution of ThermoFisher Scientific Invitrogen DAPI (a 
nuclear fluorescent stain) in 3% BSA, PBS, and incubated for 1 hour at RT away from 
light. Following the incubation, the cover slips were rinsed twice with PBS-T, and twice 
with RNase-free water. 20uL of Invitrogen Fluoromount-G Mounting Medium was added 
directly to each slide, and cover slips were mounted cell-side down on top. Slides were 
air-dried for 5 minutes before examination with the immunofluorescent microscope. 
Microscope used Nikon NIS Elements Advanced Research Imaging Software for 
computer imaging.  
 
Preparation of Solutions 
Table 6: Recipes for Solutions Prepared for Immunofluorescence Staining and 
Western Blotting.  
Solution Recipe 
PBS-T 50 mL pH 7.4 PBS 
50 uL Tween 20 Detergent 
 
Mix thoroughly using vortex.  
TBS-T 50 mL TBS 
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50 uL Tween 20 Detergent  
 
Mix thoroughly using vortex.  
TBS-T with 5% Milk 50 mL TBS-T (see above) 
5g Powdered Milk 
 
Measure milk using scale. Mix thoroughly 
using vortex.  
 
 
Negative Control  
A negative control (NC) was used for miR-24. The NC was a scrambled miRNA that 




Selection of Cell Line 
 
 
Figure 4: Relative Expression of miRNA-24-3p in Different Cell Lines. Relative 
expression of miR-24-3p compared to U6 in different human cell lines. U6 is a non-
coding, small nuclear RNA that acts as a control for miRNA expression. DMS114 is a 
small cell lung cancer cell line, MCF7 is a hormone-dependent breast cancer cell line, 
MDA231 is a hormone-independent breast cancer cell line, A549 is an epithelial cell lung 


































Figure 5: Relative Transcription of miRNA in MCF-7 Cells. Relative transcription 
levels of a negative control (NC) and miR-24 following transfection. Each 2cm plate was 
transfected with 30pmol of miRNA. Transfection time was 96 hours with a media change 






Figure 6: Exosome Expression of miRNA Following Transfection in MCF-7. 
Relative transcription of miRNA compared to U6 within exosomes secreted by MCF-7 




Figure 7: Western Blot of Expression of AGO2 in MCF-7 Cells. Relative AGO2 
protein expression in whole cell lysate (WCL) and exosomes (EXO) extracted from 
MCF-7 mock, NC, and miR-24-3p cells. Time (right) indicates the length of time that the 











































Initial Immunofluorescence Staining  
 
 
Figure 8: Immunofluorescence Staining of Control MCF-7 Cells. Control transfection 
for 8 hours with immediate fixation. DAPI staining (A, C) and 488-tagged miR-24 







Figure 9: Immunofluorescence Staining of MCF-7 Cells. Transfected with miR-24 for 
8 hours with immediate fixation. DAPI staining (A, C) and 488-tagged miR-24 staining 










Figure 10: Immunofluorescence Staining of MCF-7 Cells Transfected with 2.5 uL of 
miR-24. Transfected with miR-24 for 24 hours, and fixed 24 hours following a media 
change. DAPI staining (A, C) and 488-tagged miR-24 staining (B, D). Objective 
magnification of 60X, total magnification of 600X (A, B) (C, D are zoomed 





Figure 11: Immunofluorescence Staining of MCF-7 Cells Transfected with 7.5 uL of 
miR-24. Transfected with miR-24 for 24 hours, and fixed 24 hours following a media 
change. DAPI staining (A, C) and 488-tagged miR-24 staining (B, D). Objective 
magnification of 60X, total magnification of 600X (A, B) (C, D are zoomed 






Figure 12: Immunofluorescence Staining of MCF-7 Cells Transfected with 25 uL of 
miR-24. Transfected with miR-24 for 24 hours, and fixed 24 hours following a media 
change. DAPI staining (A, C) and 488-tagged miR-24 staining (B, D). Objective 
magnification of 60X, total magnification of 600X (A, B) (C, D are zoomed 







Figure 13: Immunofluorescence Staining of MCF-7 Cells Transfected with 250 uL 
of miR-24. Transfected with miR-24 for 24 hours, and fixed 24 hours following a media 
change. DAPI staining (A, C, E, G) and 488-tagged miR-24 staining (B, D, F, H). 
Objective magnification of 60X, total magnification of 600X (A, B, D, E) (C, D, and G, 





Figure 14: Immunofluorescence Staining of MCF-7 Cells Transfected with 2.5 uL vs 
250uL of miR-24. Transfected with miR-24 for 24 hours, and fixed 24 hours following a 
media change. DAPI staining of 2.5uL of miR-24 (A) and 488-tagged miR-24 staining 
(B). DAPI staining of 250uL of miR-24 (C) and 488-tagged miR-24 staining (D). 






Figure 15: Immunofluorescence Staining of MCF-7 Cells Transfected with 25 uL vs 
250uL of miR-24. Transfected with miR-24 for 24 hours, and fixed 24 hours following a 
media change. DAPI staining of 25uL of miR-24 (A) and 488-tagged miR-24 staining 
(B). DAPI staining of 250uL of miR-24 (C) and 488-tagged miR-24 staining (D). 





Immunofluorescence Staining: Control vs miR-24 
 
Figure 16: IF Staining of MCF-7 Cells, 100uL Transfection, 6h. Transfected with 
100uL of miR-24 for 24 hours, and fixed 6 hours following a media change. Control 
group was transfected with transfected reagent but without miR-24. DAPI staining (A, C) 
and 488-tagged miR-24 staining (B, D). Objective magnification of 100X, total 






Figure 17: Immunofluorescence Staining of MCF-7 Cells, 100uL Transfection, 18h. 
Transfected with miR-24 for 24 hours, and fixed 18 hours following a media change. 
Control group was transfected with transfected reagent but without miR-24. DAPI 
staining (A, C) and 488-tagged miR-24 staining (B, D). Objective magnification of 100X, 






Figure 18: Immunofluorescence Staining of MCF-7 Cells, 100uL Transfection, 24h, 
Low Magnification. Transfected with miR-24 for 24 hours, and fixed 24 hours following 
a media change. Control group was transfected with transfected reagent but without miR-
24. DAPI staining (A, C) and 488-tagged miR-24 staining (B, D). Objective 






Figure 19: IF Staining of MCF-7 Cells, 100uL Transfection, 24h, High 
Magnification. Transfected with miR-24 for 24 hours, and fixed 24 hours following a 
media change. Control group was transfected with transfected reagent but without miR-
24. DAPI staining (A, C) and 488-tagged miR-24 staining (B, D). Objective 




Figure 20: IF Staining of MCF-7 Cells, 100uL Transfection, miR-24. Transfected 
with miR-24 for 24 hours, and fixed 6 hours (A), 18 hours (B), and 24 hours (C) 
following a media change. 488-tagged miR-24 staining in all images. Objective 





 The purpose of this project was to test the hypothesis that miR-24 is found in 
exosomes, and can utilize exosomal protection to move between cells. It also aimed to 
demonstrate that when MCF-7 cells are transfected with miR-24, the miR-24 will 
translocate to the nucleus, where it will then be able to bind its conserved targets in 
3’UTRs and influence transcription.  
To find a suitable human cell line for testing, relative expression of miR-24 was 
measured compared to the control snRNA, U6, in a variety of different human cell lines 
(Figure 4). It was important to choose a cell line that expressed low endogenous levels of 
miR-24 so in subsequent experiments, miRNA quantification would exclusively represent 
the miRNA introduced into the cells via transfection. Figure 5 shows that the chosen 
MCF-7 cell line is a good candidate for miRNA transfection, demonstrated by the 
significant increase in transcription of the miR-24 following transfection. It was also 
important to use a cell line where miR-24 was able to integrate into exosomes.  This was 
demonstrated in the MCF-7 cell line, as miR-24 showed particularly high exosomal 
expression following transfection (Figure 6) demonstrating that it has a particular affinity 
for integration into exosomes. Based on cell line accessibility, its quick rate of cell 
growth, and its ability to integrate transfected miR-24, MCF-7 was chosen as the ideal 
cell line to use to test the hypotheses. Additionally, as a breast cancer cell line, using this 
cell line would show a direct clinical application of the experimental findings to a human 
disease state.   
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 A western blot confirmed that AGO2 is highly expressed in exosomes extracted 
from miR-24-transfected MCF-7 cells (Figure 7). While all conditions showed similar 
AGO2 expression in the whole cell lysate, only the miR-24 exosomes had significant 
AGO2 expression. Figure 7 does also show high Actin expression in miR-24 exosomes, 
meaning that the AGO2 expression demonstrated could be a result of cellular 
contamination. However, high AGO2 expression in miR-24 exosomes is consistent with 
previous research, and the proposal that the AGO2 protein is important to the function of 
miR-24.  
 The next goal was to show the translocation of miR-24 into the nucleus after 
transfection via immunofluorescent staining. A miR-24 sample was fluorescently tagged 
with ThermoFischer Scientific Alexa Fluor 488 dye. This dye allowed miR-24 to 
fluoresce green when viewed with an immunofluorescence microscope. Parental MCF-7 
cells were transfected with miR-24-488 and fixed for slide preparation. The cells can be 
seen after an 8-hour transfection in Figures 8-9. While the nuclei are visible with DAPI 
staining, miR-24 staining was not seen in either the control or the miR-24 samples. Any 
green staining was determined to be non-specific and not representative of miR-24 
entering cells. Repeat experiments with the same conditions produced similar results. 
These results did not support the initial hypothesis and were inconsistent with the 
previous RT-qPCR and western blot results. Before proceeding with subsequent testing, 
it was necessary to troubleshoot why the immunofluorescent staining failed to support the 
previous results, as well as supporting literature. Because the transfection procedure was 
the same procedure used for western blotting and exosome isolation, it seemed unlikely 
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that the problem was with the protocol for the transfection itself. A new bottle of 
RNAiMAX, the transfection reagent, was used to ensure the transfection reagent had not 
expired or become contaminated. Different samples of miR-24-488 were used to ensure 
that the miRNA sample was not contaminated, and the presence of background staining 
suggested it was not an issue with the fluorescence of the miRNA. Additionally, all cell 
culture media and transfection reagents were replaced to ensure that there was no 
contamination from the initial expansion of the cell line.  
It was deemed that the most likely cause of the failed imaging was one of two 
problems: the duration of the miRNA transfection was too short, or the quantity of 
miRNA used for the transfection was too low. Previously, the time between transfection 
and fixation transfection had ranged from 1 to 24 hours, and a longer transfection period 
and time between media change and fixation would give miR-24 more time to translocate 
to the nucleus. Until this point, the MCF-7 cells had been transfected with 2.5uL of 
miRNA, the same concentration used for exosome, protein, and RNA extraction used for 
RT-qPCR and western blots. Based on these two predictions, a new experimental 
procedure was devised for another immunofluorescent staining. Cells were left in the 
transfection reagent for 24 hours before a media change, and then fixed for staining 24 
hours later. Cells were transfected with different concentrations of miR-24 to assess what 
the optimal concentration would be for immunofluorescent staining. Because the purpose 
of this experiment was solely to identify the best transfection practice for miR-24 
fluorescence, no control was necessary. Figures 10-15 show the resultant images that 
compare the different concentrations. In these images, miR-24-488 is visible as green 
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staining in the fluorescence microscope. The miR-24 is best seen in the 250uL 
transfection (Figures 13-15), with some staining in the 25uL transfection images as well. 
Based on these results, it was determined that a concentration of approximately 100uL 
was ideal for a subsequent transfection, as it should provide enough miRNA for nuclear 
staining without utilizing excessive miR-24-488 sample.  
 Once the optimal conditions for the transfection and immunofluorescence were 
established, another transfection with a control group was completed for a final 
immunofluorescent staining. These images are shown in Figures 16-20. Here, the control 
groups show DAPI nuclear staining and negligible green miR-24 staining for all time 
points. The miR-24-transfected group shows notable and consistent green fluorescence, 
representing the transfected miRNA. As initially hypothesized, most of the staining is 
localized to the cell nucleus, showing that the miRNA translocates into the nucleus where 
it can interact with mRNA and influence gene transcription. For the miR-24-488, all three 
time periods showed similar staining for both DAPI and miR-24 staining, seen in Figure 
20. 
 The next step for the experiment was to repeat a similar transfection and 
immunofluorescence staining using miR-24-transfected exosomes, extracted from 
parental MCF-7 cells, and transfected into a new culture. However, due to time 
constraints set for the purpose of this thesis, and experimental difficulties throughout the 
course of the project, these experiments have not yet been completed. If the hypothesis is 
correct, this particular experiment would show that not only can exosomal miR-24 be 
introduced into new cells, but this miR-24 can translocate to the nucleus where it can 
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subsequently bind its mRNA targets. Thus, these experiments would illustrate the ability 
of miRNA to be packaged into exosomes by one cell, and engulfed by another cell where 
the miRNA then translocates into a new nucleus.  
 If miRNA can move into the nucleus of a foreign cell, miRNA can influence 
transcription outside of the cell in which it is produced. Its ability to integrate into 
exosomes indicates that it is capable of traveling within the body and influencing protein 
expression on a much broader scale than if it was tethered to its primary cell. In a disease 
state, exosomes containing miR-24 may be taken up into circulating tumor cells, where 
miRNA can influence transcription in cancerous cells, influencing prospective metastasis. 
miR-24 may then be used as a target for a determination of cancer prognosis or diagnosis, 
aiding the current ability to use circulating tumor cells as a biomarker for disease. It was 
demonstrated that AGO2 was upregulated with miR-24 expression, and AGO2 detection 
may be used similarly. miR-24 was shown to upregulate its neighboring genes, and is 
well-established in its ability to suppress transcription by binding 3’UTRs. Future 
research should investigate its ability to upregulate its own transcription. If miRNA has 
this capability, it would be able to increase its own transcription exponentially, further 
enhancing its influence over genetic expression.  
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